Nectar Lifesciences Limited has informed the Exchange about Corrigendum to the Notice of 2025-26/01st Extraordinary General Meeting
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Nectar Lifesciences has issued a corrigendum to the notice of its 1st Extraordinary General Meeting (EGM) scheduled for August 4, 2025. The Board of Directors, in a meeting on July 23, 2025, clarified the mode of rewarding shareholders mentioned in the explanatory statement of Item No. 3 of the EGM notice. Earlier, the notice vaguely mentioned 'rewarding shareholders' from the proceeds of a Proposed Transaction; now it has been explicitly elaborated to mean special dividends, Buyback of Equity Shares, or a mix of both. The Proposed Transaction proceeds are intended for debt repayment, investment in new projects, rewarding shareholders, and general corporate purposes. Apart from this clarification, all other contents of the original EGM notice remain unchanged.
Positive for shareholders — the company has now explicitly signalled that returns from a proposed transaction could come back to investors via special dividends, share buyback, or a combination. This adds clarity and a tangible potential upside, though actual buyback/dividend quantum will depend on the Proposed Transaction being approved and the Board's final decision.